Home
Sumitomo Dainippon Pharma Oncology

七月 2026的Sumitomo Dainippon Pharm...市场份额分析

sumitomo pharma oncology is a global developer of novel cancer therapeutics. learn about our diverse and purposeful pipeline of targeted therapies.

健康 > 生物科技及制药

域sdponcology.com

成立年份2020

员工201 - 500

年营收--

Sumitomo Dainippon Pharma Oncology

Sumitomo Dainippon Pharma Oncology（包含公司地区分支机构）

sdponcology.com

查看更多网站流量和参与度信息

Sumitomo Dainippon Pharma Oncology热门域名的总访问量

了解Sumitomo Dainippon Pharma Oncology市场份额和潜在市场覆盖范围。

过去 3 个月的总访问量

无数据可显示

Sumitomo Dainippon Pharma Oncology热门域名的平均访问时长

分析Sumitomo Dainippon Pharma Oncology参与度指标。

过去 3 个月的平均访问时长

无数据可显示

Sumitomo Dainippon Pharma Oncology热门域名的平均页面浏览量

了解Sumitomo Dainippon Pharma Oncology如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。

过去 3 个月的平均页面浏览量

无数据可显示

Sumitomo Dainippon Pharma Oncology 排名靠前的竞争对手（按域名）

似乎没有足够的数据。

无数据可显示

Sumitomo Dainippon Pharma Oncology 采用的主要技术

这些是排名前 Sumitomo Dainippon Pharma Oncology 的顶级域名所使用的网站技术（按行业分列）

付费广告 (2)

DoubleClick

小部件 (2)

reCAPTCHA

视听媒体 (1)

YouTube

商务解决方案 (1)

DocuSign

更多技术

7

查看全部

Sumitomo Dainippon Pharma Oncology 的新闻与信号

借助 Similarweb 销售信号提醒，每当在目标受众之中出现新的机会或威胁时，您都会收到所识别出购买信号的每日更新。

新闻Sumitomo Dainippon Pharma Oncology, Inc. hired Jatin J. Shah as Executive Vice President, Chief Medical Officer and Global Head of Development on Feb 22nd '22.Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage pharmaceutical company focused on research and development for novel cancer therapeutics, today announced the appointment of Jatin J. Shah, M.D. as Executive Vice President, Chief Medical Officer and Global Head of Development.

新闻Sumitomo Dainippon Pharma Oncology, Inc. launched Phase 3 WIZARD 201G study on Dec 15th '21.Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage biopharmaceutical company focused on research and development for novel cancer therapeutics, today announced that the Phase 3 WIZARD 201G study will terminate following its second interim analysis after determining there is a low probability of meeting the primary endpoint of overall survival at the final analysis.

新闻Sumitomo Dainippon Pharma Oncology, Inc. launches CanStem303C study.Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that the CanStem303C study evaluating the efficacy and safety of investigational agent napabucasin when given in combination with FOLFIRI with or without bevacizumab in patients with previously treated metastatic colorectal cancer failed to reach the primary endpoints of overall survival (OS).